Triple

T9807110
Position Surface form Disambiguated ID Type / Status
Subject Actemra E238180 entity
Predicate hasActiveIngredient P12771 FINISHED
Object tocilizumab E238180 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: tocilizumab | Statement: [Actemra, hasActiveIngredient, tocilizumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: tocilizumab
Context triple: [Actemra, hasActiveIngredient, tocilizumab]
  • A. Actemra chosen
    Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
  • B. ocrelizumab
    Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
  • C. Humira
    Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
  • D. Taltz
    Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
  • E. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ca84defac48190abc1148804f184c1 completed March 30, 2026, 2:12 p.m.
NER Named-entity recognition batch_69cdab7cb9588190953a063cb7b9e29e completed April 1, 2026, 11:34 p.m.
NED1 Entity disambiguation (via context triple) batch_69d1cc57119881909616d835def02fc9 completed April 5, 2026, 2:43 a.m.
Created at: March 30, 2026, 8:29 p.m.